COMMUNIQUÉS West-GlobeNewswire

Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.
08/05/2025
May 8, 2025 Announcement no. 15 Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained. Interim results and a business update for the first [...]
Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook
08/05/2025
COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains [...]
Swarm Oncology to present at Bio€quity Europe 2025
08/05/2025
London, U.K., May 8 2025 , Swarm Oncology Ltd. (“Swarm Oncology” or “the Company”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, today [...]
Interim report Q1 2025
08/05/2025
Strong start to the year and confirmed full-year outlook Ester Baiget, President & CEO: “ We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. [...]
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General Business Update
08/05/2025
Oslo, Norway, 8 May 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces its first quarter 2025 results [...]
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC [...]
Zealand Pharma Announces Financial Results for the First Three Months of 2025
08/05/2025
Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and [...]
Pharming Group reports first quarter 2025 financial results and provides business update
08/05/2025
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued [...]
Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-human in vivo liver-directed ISLV gene therapy for MMA
08/05/2025
Milan, ITALY – 8 May 2025 – Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announces an upcoming oral presentation showcasing [...]
Vancouver-Based Delfi Medical Innovations Takes Blood Flow Restriction Technology to New Heights — Literally
08/05/2025
VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Delfi Medical Innovations Inc., a global leader in blood flow restriction (BFR) technology based in Vancouver, is proud to announce that its equipment has [...]
Ashvattha Therapeutics to Present Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Disease at ARVO
07/05/2025
Subcutaneous administration generally safe and well-tolerated across multiple doses >80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75% total reduction in fellow eyes [...]
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
07/05/2025
Additional Gross Proceeds of Approximately $1.3 Million Received Upon Exercise of Certain Warrants Issued in the Public Offering MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. (“Pasithea,” or the “ [...]
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
07/05/2025
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra- [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/05/2025
CLEVELAND, May 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]
Viemed Healthcare Announces First Quarter 2025 Financial Results
07/05/2025
LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced [...]
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
07/05/2025
Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increase Product Revenues in the first in the first quarter of 2025 reached [...]
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
07/05/2025
Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increase Product Revenues in the first in the first quarter of 2025 reached [...]
Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025
07/05/2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/05/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 07 mai 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]

Pages